How does retatrutide make you feel? It is a question many people ask as interest grows in this investigational triple receptor agonist being studied for obesity and type 2 diabetes. Retatrutide simultaneously activates GLP-1, GIP, and glucagon receptors, producing wide-ranging effects on appetite, digestion, and metabolism. Understanding the sensations associated with retatrutide — from reduced hunger and gastrointestinal discomfort to fatigue and injection-site reactions — is essential for anyone considering or currently participating in a clinical trial. This article draws on published Phase 2 trial data to explain what participants commonly experience and when to seek medical advice.

What Is Retatrutide and How Does It Work in the Body

Retatrutide is an investigational once-weekly subcutaneous injection that activates GLP-1, GIP, and glucagon receptors simultaneously, slowing gastric emptying, reducing appetite, enhancing insulin secretion, and potentially increasing energy expenditure.

Retatrutide is an investigational medicine that has not yet received marketing authorisation from the Medicines and Healthcare products Regulatory Agency (MHRA) or the European Medicines Agency (EMA). It is currently only available within clinical trial settings and is being evaluated for the treatment of obesity and type 2 diabetes.

Retatrutide is a triple receptor agonist, meaning it is designed to activate three distinct hormone receptors simultaneously: the glucagon-like peptide-1 (GLP-1) receptor, the glucose-dependent insulinotropic polypeptide (GIP) receptor, and the glucagon receptor. This distinguishes it from dual agonists such as tirzepatide and single agonists such as semaglutide, though no head-to-head comparative trials have been conducted and no superiority claims can be made at this stage.

Activating GLP-1 receptors slows gastric emptying, reduces appetite, and enhances insulin secretion in a glucose-dependent manner.^[3][4] The role of GIP receptor activation is not fully understood; it has been hypothesised to complement GLP-1 activity, though evidence in humans remains limited. The glucagon receptor component is thought — largely on the basis of preclinical data — to increase energy expenditure and promote fat breakdown (lipolysis), which may contribute to the substantial weight loss observed in early trials; however, the precise contribution of this mechanism in humans is still being investigated.

Retatrutide is administered as a once-weekly subcutaneous injection, based on the dosing schedule used in Phase 2 trials.^[1][2] Because it acts on multiple hormonal pathways, its effects on appetite, digestion, and metabolism can be wide-ranging, which is why understanding the range of sensations associated with this medicine is important for anyone considering or currently participating in a clinical trial.

Common Side Effects and Sensations Reported With Retatrutide

The most common sensations are gastrointestinal — particularly nausea, diarrhoea, and pronounced fullness — which are dose-dependent, typically mild to moderate, and tend to improve over time.

Based on data from Phase 2 clinical trials — including the pivotal randomised controlled trial published in The New England Journal of Medicine in 2023 (Jastreboff et al.) — the most frequently reported sensations and side effects with retatrutide are largely gastrointestinal (GI) in nature. These are consistent with the broader class of GLP-1-based therapies and include:

• Nausea — the most commonly reported symptom, particularly during dose escalation

• Vomiting — less frequent than nausea but reported, especially at higher doses

• Diarrhoea — often transient and associated with early treatment phases

• Constipation — some participants report alternating bowel habits

• Decreased appetite — a desired pharmacological effect, though it can feel uncomfortable initially

• Belching and bloating — related to slowed gastric emptying

Additional effects reported with retatrutide or with medicines in the same class include:

• Injection-site reactions — such as redness, itching, or mild discomfort at the injection site

• Headache and dizziness — particularly during early treatment

• Small increases in heart rate — modest elevations have been observed with GLP-1-based therapies; the clinical significance in most individuals is uncertain but should be monitored^[1][8]

• Gallbladder-related events — including gallstones (cholelithiasis), which have been associated with GLP-1 receptor agonists and with rapid weight loss more generally^[8][9]

Many participants also describe a general feeling of fullness after eating very small amounts of food, which is a direct consequence of delayed gastric emptying. Some individuals report fatigue, particularly during the initial weeks of treatment or following dose increases; this may be related to reduced caloric intake, though the precise cause is not fully established and persistent fatigue should be discussed with the trial team.

The intensity of GI symptoms tends to be dose-dependent — higher doses are associated with more pronounced effects. In clinical trials, a gradual dose-escalation schedule was used specifically to allow the body to adapt and to minimise discomfort. Most participants found that GI symptoms improved over time. It is important to note that current safety information is based on Phase 2 data and may evolve as larger Phase 3 trials report their findings.

Managing Uncomfortable Symptoms During Treatment

GI symptoms can be managed through smaller, more frequent meals, avoiding fatty or spiced foods, staying well hydrated, and following the trial team's dose-escalation schedule; always consult the trial team before using any over-the-counter remedies.

For those participating in retatrutide clinical trials, managing side effects is an important part of the treatment experience. While healthcare teams overseeing trials provide specific guidance, there are several general strategies that may help reduce discomfort, particularly from GI symptoms.

Dietary adjustments are often the first line of self-management:

• Eat smaller, more frequent meals rather than large portions

• Avoid high-fat, greasy, or heavily spiced foods, which can worsen nausea

• Eat slowly and chew food thoroughly

• Stay well hydrated, particularly if experiencing diarrhoea or vomiting; oral rehydration solutions (such as those recommended on NHS.uk) can be helpful if fluid loss is significant

• Avoid lying down immediately after eating

• Limit alcohol whilst symptomatic, as it may worsen nausea and affect blood sugar levels

For nausea specifically, eating bland foods such as plain crackers, toast, or rice may help. Ginger-based products (ginger tea or ginger biscuits) are commonly used as a complementary measure, though evidence for their efficacy in drug-induced nausea is limited.

Before using any over-the-counter remedies — including antiemetics, antidiarrhoeals, antacids, or herbal products — always consult your trial team first, as some products may interact with the trial medicine or affect assessments.

Fatigue can often be managed by ensuring adequate rest and maintaining gentle physical activity where possible. It is important not to significantly restrict fluid or food intake beyond what the medication naturally induces, as this can lead to nutritional deficiencies or dehydration.

Participants should always follow the dose-escalation schedule provided by their trial team and should not attempt to self-adjust their dose. Slowing the escalation pace is sometimes clinically appropriate and should be discussed with the supervising clinician rather than managed independently. Keeping a symptom diary can be a useful tool to track patterns and share accurate information with the healthcare team.

When to Seek Medical Advice About How You Are Feeling

Seek emergency care for signs of anaphylaxis or severe abdominal pain suggesting pancreatitis; contact your trial team or NHS 111 promptly for persistent vomiting, dehydration, hypoglycaemia symptoms, or significant mood changes.

Whilst many of the sensations associated with retatrutide are expected and manageable, certain symptoms warrant prompt medical attention. Anyone participating in a clinical trial should be familiar with these warning signs and should not hesitate to contact their trial team or GP.

Call 999 or go to your nearest A&E immediately if you experience:

• Signs of a severe allergic reaction (anaphylaxis), including swelling of the face, lips, tongue, or throat, difficulty breathing, or a widespread rash with collapse

Seek urgent medical advice if you experience:

• Severe or persistent vomiting that prevents you from keeping fluids down

• Signs of dehydration, including dizziness, dark urine, or significantly reduced urination

• Severe abdominal pain, particularly if it radiates to the back — this may indicate pancreatitis, a rare but serious adverse effect associated with GLP-1 receptor agonists^[11][12]

• Pain in the upper right abdomen, fever, yellowing of the skin or eyes (jaundice), pale stools, or dark urine — these may be signs of a gallbladder problem, such as gallstones or cholecystitis, which have been associated with this class of medicine and with rapid weight loss

• Symptoms of hypoglycaemia (low blood sugar), such as shakiness, sweating, confusion, or palpitations — the risk is higher if you are also taking insulin or a sulfonylurea; follow your trial team's hypoglycaemia management plan

• Severe or persistent changes in mood, or any thoughts of self-harm or suicide — whilst a causal link between GLP-1-based medicines and mood changes has not been established (regulatory reviews, including by the EMA, are ongoing), any significant psychological symptoms should be reported promptly^[13][14]

• Any allergic reaction, including rash or skin changes

It is also important to report any new or worsening symptoms to your trial team, even if they seem minor. Clinical trials have robust pharmacovigilance processes, and reporting all symptoms contributes to the overall safety profile of the medicine.

In the UK, the MHRA oversees the safety of medicines in clinical trials. Participants are also encouraged to report suspected side effects directly via the MHRA Yellow Card Scheme at yellowcard.[18]mhra.gov.uk, in addition to notifying their trial team. Participants have the right to withdraw from a trial at any time without it affecting their standard NHS care. If you are unsure whether a symptom is serious, contacting your GP or calling NHS 111 is always appropriate.

What Current Evidence and Clinical Trials Tell Us

The key published evidence is a 2023 Phase 2 RCT (Jastreboff et al.) showing substantial weight loss and predominantly mild-to-moderate GI side effects; Phase 3 trials are ongoing and retatrutide remains unapproved for routine clinical use.

Retatrutide remains an investigational medicine and has not yet received marketing authorisation from the MHRA or the EMA. It is therefore not currently available as a prescribed treatment outside of clinical trial settings.

The most significant published data comes from a Phase 2 randomised controlled trial published in The New England Journal of Medicine in 2023 (Jastreboff et al.^[1]), which evaluated retatrutide across multiple doses in adults with obesity. Key findings included:

• Weight loss of up to 24.2% of body weight at 48 weeks — this figure was observed in adults without type 2 diabetes receiving the highest dose with a protocolised titration schedule; results varied across dose groups and this context is important when interpreting the data

• GI side effects were the most common adverse events, consistent with the GLP-1 class, and were predominantly mild to moderate in severity, declining over time

• Small increases in heart rate and gallbladder-related events were also observed, consistent with class effects

• The trial was of limited duration; longer-term safety data are not yet available

Phase 3 trials are ongoing and will provide more comprehensive data on long-term safety, cardiovascular outcomes, and quality of life. Until those results are available and regulatory review is complete, retatrutide's full benefit–risk profile remains to be established.

It is important to approach emerging data with appropriate caution. Whilst early results are promising, retatrutide is not approved for clinical use, and any claims about its effects outside of peer-reviewed trial data should be viewed critically.

Patients interested in retatrutide should speak with their GP or a specialist. For up-to-date information on clinical trials in the UK, the NIHR 'Be Part of Research' portal (bepartofresearch.nihr.ac.uk) is the recommended patient-facing resource. International trial listings can be found at ClinicalTrials.gov and the EU Clinical Trials Register (CTIS).

Frequently Asked Questions